Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 191–200 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 191

    Medicine slug
    bosentan
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 5 hours

      Numeric value
      5
      Unit
      hours
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:749e42fb-2fe0-45dd-9268-b43bb3f4081c (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics General After oral administration, maximum plasma concentrations of bosentan are attained within 3–5 hours and the terminal elimination half-life is about 5 hours in healthy adult subjects.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:540b6f6a-79f3-4681-8c2a-268cf7cecbc9 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics General After oral administration, maximum plasma concentrations of bosentan are attained within 3–5 hours and the terminal elimination half-life is about 5 hours in healthy adult subjects.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8444da17-6c31-492b-8842-93740f083d9d (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics General After oral administration, maximum plasma concentrations of bosentan are attained within 3 hours to 5 hours and the terminal elimination half-life is about 5 hours in healthy adult subjects.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c006d8ef-8cb7-4fb3-88eb-b2debc302a20 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics General After oral administration, maximum plasma concentrations of bosentan are attained within 3 to 5 hours and the terminal elimination half-life is about 5 hours in healthy adult subjects.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1e75179-cbea-4535-8709-f6d79c1d4004 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics General After oral administration, maximum plasma concentrations of bosentan are attained within 3 hours to 5 hours and the terminal elimination half-life is about 5 hours in healthy adult subjects.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39b2a85f-4322-42d4-b420-1b1d52569143 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics General After oral administration, maximum plasma concentrations of bosentan are attained within 3 to 5 hours and the terminal elimination half-life is about 5 hours in healthy adult subjects.

  2. Projected row 192

    Medicine slug
    bosentan
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    6
    Source count
    6
    Agreement rate
    1
    Recorded readings

    1. 18 L

      Numeric value
      18
      Unit
      L
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:749e42fb-2fe0-45dd-9268-b43bb3f4081c (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        The volume of distribution is about 18 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:540b6f6a-79f3-4681-8c2a-268cf7cecbc9 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        The volume of distribution is about 18 L.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8444da17-6c31-492b-8842-93740f083d9d (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        The volume of distribution is about 18 L.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c006d8ef-8cb7-4fb3-88eb-b2debc302a20 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        The volume of distribution is about 18 L.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1e75179-cbea-4535-8709-f6d79c1d4004 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        The volume of distribution is about 18 L.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39b2a85f-4322-42d4-b420-1b1d52569143 (opens source in a new tab)

        Bosentan label

        Version not recorded · Effective date not recorded

        The volume of distribution is about 18 L.

  3. Projected row 193

    Medicine slug
    bosutinib
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 34%

      Numeric value
      34
      Unit
      %
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb7a8d1d-07c0-462d-960f-214d44705e76 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        The absolute bioavailability was 34% in healthy subjects.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        The absolute bioavailability was 34% in healthy subjects.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adc84ad5-a04d-4fee-9ba8-91f7abd928e3 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        The absolute bioavailability was 34% in healthy subjects.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5929f91-6496-4c0e-97e8-0bd524e15763 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        The absolute bioavailability was 34% in healthy subjects.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ea1617f-41d3-479a-87d5-177013d39193 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        The absolute bioavailability was 34% in healthy subjects.

  4. Projected row 194

    Medicine slug
    bosutinib
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    5
    Agreement rate
    1
    Recorded readings

    1. 94%

      Numeric value
      94
      Unit
      %
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb7a8d1d-07c0-462d-960f-214d44705e76 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        Bosutinib protein binding is 94% in vitro and 96% ex vivo, and is independent of concentration.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f3e9739-8ec1-4ea9-b1bc-185fd07d84e4 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        Bosutinib protein binding is 94% in vitro and 96% ex vivo, and is independent of concentration.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adc84ad5-a04d-4fee-9ba8-91f7abd928e3 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        Bosutinib protein binding is 94% in vitro and 96% ex vivo , and is independent of concentration.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5929f91-6496-4c0e-97e8-0bd524e15763 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        Bosutinib protein binding is 94% in vitro and 96% ex vivo , and is independent of concentration.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ea1617f-41d3-479a-87d5-177013d39193 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        Bosutinib protein binding is 94% in vitro and 96% ex vivo, and is independent of concentration.

  5. Projected row 195

    Medicine slug
    bosutinib
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    5
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adc84ad5-a04d-4fee-9ba8-91f7abd928e3 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        The bosutinib median (min, max) t max is approximately 3 hours post-dose (1, 8 hours).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5929f91-6496-4c0e-97e8-0bd524e15763 (opens source in a new tab)

        Bosutinib label

        Version not recorded · Effective date not recorded

        The bosutinib median (min, max) t max is approximately 3 hours post-dose (1, 8 hours).

  6. Projected row 196

    Medicine slug
    brexpiprazole
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    4
    Agreement rate
    1
    Recorded readings

    1. 95%

      Numeric value
      95
      Unit
      %
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df891816-3fdb-4347-8bf0-c18bc40f1d70 (opens source in a new tab)

        Brexpiprazole label

        Version not recorded · Effective date not recorded

        cokinetics Absorption After single-dose administration of REXULTI tablets, the peak plasma brexpiprazole concentrations occurred within 4 hours after administration, and the absolute oral bioavailability was 95%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2d301358-6291-4ec1-bd87-37b4ad9bd850 (opens source in a new tab)

        Brexpiprazole label

        Version not recorded · Effective date not recorded

        cokinetics Absorption After single-dose administration of REXULTI tablets, the peak plasma brexpiprazole concentrations occurred within 4 hours after administration, and the absolute oral bioavailability was 95%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

        Brexpiprazole label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After single-dose administration of brexpiprazole tablets, the peak plasma brexpiprazole concentrations occurred within 4 hours after administration, and the absolute oral bioavailability was 95%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6991c065-0f6e-433a-8f4f-796e0ece327f (opens source in a new tab)

        Brexpiprazole label

        Version not recorded · Effective date not recorded

        cokinetics Absorption After single-dose administration of REXULTI tablets, the peak plasma brexpiprazole concentrations occurred within 4 hours after administration, and the absolute oral bioavailability was 95%.

  7. Projected row 197

    Medicine slug
    brimonidine
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    22
    Source count
    17
    Agreement rate
    0.588235
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      10

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 10 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8e108b3-aca8-4e3e-8577-37ac796148c3 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee26e0c9-a169-4842-ab0f-3c718bb14018 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4b04ef1-6586-4386-a844-2c5fc3bd4a8f (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:264c4494-c225-486f-888a-caaf36be46b3 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5c4aea88-95ca-4da8-a3da-02f10c8b6623 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64b21e68-610c-5194-ccb2-9d9f6ff8cda9 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e08a915a-77ca-4d16-d760-11b05848418d (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:981a75cd-2487-40e4-911a-26de2aa98dc1 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9da815fb-6454-4925-9150-bec40eff9c2d (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87c5a534-4321-46c7-9938-84dca34b6506 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of either a 0.1% or 0.2% solution, plasma concentrations peaked within 0.5 to 2.5 hours and declined with a systemic half-life of approximately 2 hours.

    2. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      6

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 6 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:383421a5-5d33-4f15-88f4-8b66fcbfac71 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dfd85672-fa4b-40e3-ac9c-81b8d9e4ffde (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:865f88b0-b13e-4607-a314-939f1b331e6f (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdb8620f-adfa-4433-b285-9c42334f8600 (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75c5f708-1afb-4505-94a6-a2c0afb0aedc (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a25f7abf-e066-4d16-a0ba-6150bdace81d (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.

    3. 2.1 hours

      Numeric value
      2.1
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1e7ebd4-d0d2-40a5-aa11-5f68bc5972bd (opens source in a new tab)

        Brimonidine label

        Version not recorded · Effective date not recorded

        The systemic half-life was approximately 2.1 hours.

  8. Projected row 198

    Medicine slug
    brincidofovir
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 16.8%

      Numeric value
      16.8
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0784838e-00bd-4b14-9b7e-653b7fbb7eea (opens source in a new tab)

        Brincidofovir label

        Version not recorded · Effective date not recorded

        Absorption Bioavailability Oral suspension 16.8% Tablet 13.4% T max b 3 hours (2 to 8 hours) Effect of food on TEMBEXA Tablet (relative to fasting) c • AUC inf decreased by 31% • C max decreased by 49% Distribution % Bound to human plasma proteins >99.9% Blood-to-plasma ratio (drug or drug-related materials) d 0.48 to 0.61 Apparent Volume of distribution, L 1230 Elimination Apparent Clearance, L/h
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:209aa94b-c613-4880-ad89-41be83d12c0a (opens source in a new tab)

        Brincidofovir label

        Version not recorded · Effective date not recorded

        Absorption Bioavailability Oral suspension 16.8% Tablet 13.4% T max b 3 hours (2 to 8 hours) Effect of food on TEMBEXA Tablet (relative to fasting) c • AUC inf decreased by 31% • C max decreased by 49% Distribution % Bound to human plasma proteins >99.9% Blood-to-plasma ratio (drug or drug-related materials) d 0.48 to 0.61 Apparent Volume of distribution, L 1230 Elimination Apparent Clearance, L/h

  9. Projected row 199

    Medicine slug
    brincidofovir
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 113 hours

      Numeric value
      113
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0784838e-00bd-4b14-9b7e-653b7fbb7eea (opens source in a new tab)

        Brincidofovir label

        Version not recorded · Effective date not recorded

        The metabolite cidofovir diphosphate reaches maximum concentration at 47 hours (23 to 311 hours) following administration of the recommended dose, with a mean (CV%) half-life of 113 hours (34.2%).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:209aa94b-c613-4880-ad89-41be83d12c0a (opens source in a new tab)

        Brincidofovir label

        Version not recorded · Effective date not recorded

        The metabolite cidofovir diphosphate reaches maximum concentration at 47 hours (23 to 311 hours) following administration of the recommended dose, with a mean (CV%) half-life of 113 hours (34.2%).

  10. Projected row 200

    Medicine slug
    brincidofovir
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. >99.9%

      Numeric value
      99.9
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0784838e-00bd-4b14-9b7e-653b7fbb7eea (opens source in a new tab)

        Brincidofovir label

        Version not recorded · Effective date not recorded

        ension 16.8% Tablet 13.4% T max b 3 hours (2 to 8 hours) Effect of food on TEMBEXA Tablet (relative to fasting) c • AUC inf decreased by 31% • C max decreased by 49% Distribution % Bound to human plasma proteins >99.9% Blood-to-plasma ratio (drug or drug-related materials) d 0.48 to 0.61 Apparent Volume of distribution, L 1230 Elimination Apparent Clearance, L/hr 44.1 Mean terminal half-life (t 1/
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:209aa94b-c613-4880-ad89-41be83d12c0a (opens source in a new tab)

        Brincidofovir label

        Version not recorded · Effective date not recorded

        ension 16.8% Tablet 13.4% T max b 3 hours (2 to 8 hours) Effect of food on TEMBEXA Tablet (relative to fasting) c • AUC inf decreased by 31% • C max decreased by 49% Distribution % Bound to human plasma proteins >99.9% Blood-to-plasma ratio (drug or drug-related materials) d 0.48 to 0.61 Apparent Volume of distribution, L 1230 Elimination Apparent Clearance, L/hr 44.1 Mean terminal half-life (t 1/

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=190

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy